AIDS Research and Treatment / 2012 / Article / Tab 2

Research Article

CD4 Cell Counts at HIV Diagnosis among HIV Outpatient Study Participants, 2000–2009

Table 2

Median CD4 cell count (cells/mm3) at HIV diagnosis* by demographic characteristics and study period during which HIV diagnosis occurred, the HIV Outpatient Study, 2000–2009. Table presents only strata including at least 100 patients in the study.

2000-2001 ( )2002-2003 ( )2004-2005 ( )2006-2007 ( )2008-2009 ( )P value for trendAll years ( )

Overall, median (interquartile range)284 (99–438)298 (71–523)288 (110–501)320 (139–517)314 (90–502)0.13299 (100–498)
Overall, mean (95% confidence interval)312 (277–347)346 (306–386)341 (302–380)354 (312–396)353 (303–402)339 (321–358)
By gender
 Male ( )2723202933553050.34304
 Female ( )2872582832223740.22286
By race/ethnicity
 Non-Hispanic white ( )3623333163833520.69348
 Non-Hispanic black ( )2432722822642760.60271
By HIV infection risk group
 MSM ( )3513753083863360.80351
 Heterosexual ( )2092472292882930.09247
By medical insurer
 Privately insured ( )2843363013433280.38310
 Publicly insured ( )2302672342132940.27260
By type of facility
 Public ( )2082252772122760.10247
 Private ( )3313373103433520.32330

*For inclusion in this analysis, patients must have had a CD4 cell count measured within 1 month prior to or up to 3 months after the date of HIV diagnosis while remaining antiretroviral-naïve.
By Jonckheere-Terpstra nonparametric test for continuous variables.
Differences in CD4 counts by race/ethnicity, HIV infection risk group, insurance, and type of facility were all statistically significant (nonparametric Wilcoxon rank sum test ).

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.